These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22082712)

  • 1. Potential safety signals and their significance.
    Powers A; Cook GE
    Arch Intern Med; 2012 Jan; 172(1):72-3. PubMed ID: 22082712
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary supplements: a call to action.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):330-2. PubMed ID: 21133740
    [No Abstract]   [Full Text] [Related]  

  • 4. Panel backs pain drug studies with new safety checks.
    Dolgin E
    Nat Med; 2012 Apr; 18(4):472. PubMed ID: 22481387
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 7. Reporting adverse vaccine events.
    O'Rourke K
    J Am Vet Med Assoc; 2003 Sep; 223(6):753-4. PubMed ID: 14507079
    [No Abstract]   [Full Text] [Related]  

  • 8. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 9. Flight 483 now boarding.
    Czap A
    Altern Med Rev; 2010 Sep; 15(3):183-5. PubMed ID: 21155619
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
    Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):95-114. PubMed ID: 7613562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.
    Seruga B; Sterling L; Wang L; Tannock IF
    J Clin Oncol; 2011 Jan; 29(2):174-85. PubMed ID: 21135271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from cisapride.
    CMAJ; 2001 May; 164(9):1269, 1271. PubMed ID: 11341130
    [No Abstract]   [Full Text] [Related]  

  • 13. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C; Guglielmo BJ
    Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
    [No Abstract]   [Full Text] [Related]  

  • 14. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 15. "Black Box" warning labels and drug withdrawals.
    Thomas JA
    Toxicol Appl Pharmacol; 2002 Sep; 183(2):81. PubMed ID: 12387746
    [No Abstract]   [Full Text] [Related]  

  • 16. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database.
    Szarfman A; Doraiswamy PM; Tonning JM; Levine JG
    Arch Neurol; 2006 Feb; 63(2):299-300; author reply 300. PubMed ID: 16476828
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A challenge to the data miners.
    Lilienfeld DE;
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):881-4. PubMed ID: 15558812
    [No Abstract]   [Full Text] [Related]  

  • 20. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.